Monthly Archives: May 2024

79.99, two-notes.com

Two Notes has recently brought its hardware amp sim more in line with the rest of the pedal world its recent Opus was a much more direct competitor to things like the Iridium and UAFX amp pedals than the previous C.A.B. products and , of course, the logical extension of this is a dedicated full-signal chain VST plugin in the vein of IK Multimedias ToneX, or Neural DSPs suites. Enter, then, Genome.

Genome is a VST plugin that offers pedal, amps, cabinets and studio effects with a wide (and expandable) library of virtual gear to run your guitar through. It has just recently been updated to version 1.2, after 1.0 was officially released earlier this year (a beta was unveiled at NAMM 2022). Theres no standalone app, so youll need a DAW to host it in, but there are free options for this on every platform and realistically, if youre considering Genome, youre already making music within your DAW of choice.

Genomes UI is fairly self-explanatory, and if youve used basically any other guitar plugin before, youll get your head around whats going on pretty quickly. At the very top youve got some basic input/output monitoring and level control, and buttons for the tuner and noise gate. Above the view of whatever virtual gear youre focusing on, theres a left-to-right signal chain of 10 blocks.

Interacting with this UI is intuitive: blocks can be reordered by dragging them around, and switched out with a drop-down menu, and the virtual gears virtual controls are all clearly laid out and easily adjustable. You can split the signal chain into two parallel chains and then choose where it merges, and also pan and mix the two streams. Its very easy to get your head around, and it all happens quickly and responsively.

Using Genome I never feel lost at all not even in the preset loading menu, which lets you select from a veritable shedload of premade signal chains or save your own. Automation is relatively simple too, with controls easily assignable to various parameters.

The tuner and gate are both perfectly functional, behaving exactly as youd expect. However right now theres no pre-chain pitch-shifter that can be a handy feature for changing tunings on the fly, so its absence here is a little bit of a shame. In fact, across the entire effects range, theres nothing of any pitch variety at all (for now future updates may change this). But hows everything else?

The default starting preset is, as seems to be tradition, a super-clean Fender-inspired amp with a little compression and reverb on the end. Not the most exciting sound on the planet. However, like ordering a margherita to gauge the quality of a pizza place, the execution of the brass-tacks basics can be very telling.

Here, I find the Fendery clean thing very well-executed indeed theres a liveliness that indicates some attention to detail has been paid to what makes a clean tone not totally boring to play. Two Notes has past experience with this particular sound: its long-time flagship hardware cab sim unit, the C.A.B. M+ unit came loaded with just a single Fender-inspired preamp model, so its success here is unsurprising.

The clean tone would go great with a spring reverb, but if you do want a portion of that surf-flavoured dipping sauce, the two available spring emulations are part of the paid extra side of Genome. Its $20 for the basic spring emulation, $50 for the more complex one. Though its worth noting that compared to other similar guitar plugins, Genome is fairly affordable off the bat and so while some paid extras in the form of some of the cabinets, amps and effects might initially seem like a sting in the tail, it allows the plugin to function as a more affordable bare-bones platform, with a more focused approach to expandability.

In some ways this makes it more enticing than a pricey yet complete sandbox of infinite options with the base option being cheaper, youre likely saving money as long as you know what you want to expand out into. To help in this regard, paid-for effects can be demoed within the software.

Moving onto some higher-gain sounds, things remain realistic-sounding and familiar-feeling. Virtual fuzz and overdrive pedals interact with virtual tube amps as you would expect their real counterparts to do a RAT before an Orange gives woolly midrange saturation, and a Tube Screamer before a 5150 gives tight modern metal. Across the board, the amps are just, well, good and thats before we smack into the cresting iceberg that is CODEX. More on that in a second.

The cabinet, er, cabinet is well stocked, and of course has room for your own IRs of choice. But Two Notes DynIR captures are another one of its strengths, and its with these that I find the most instant tweakability. Various mic models and positions provide the sort of continuous tone-twiddling that, when Im building a preset from the ground up, makes it easy to achieve a natural sound.

Splitting the signal chain is very useful here, too we all know parallel drive sounds can be fun, but mixing, matching and panning different DynIR captures led to some almost completely mix-ready tones out of a single guitar track.

Its worth noting that the effects and amps selection arent as overwhelmingly huge as some plugins libraries however, in practice I often found that beyond a certain point all that really does is increase option paralysis without actually making the thing more versatile.

So, onto the CODEX amp block. This is perhaps the unsung hero of Genome, as it has the potential to glue various bits of a digital setup together in a very seamless and cool way. Compatible with Neural Amp Modeller (NAM), AIDA-X and Proteus formats , it allows you to load these amp/pedal captures, shape them with some extensive EQ, level and gain controls, and treat them as you would any other block within Genome.

While Two Notes is indeed offering paid extras to expand Genome, AIDA-X, NAM and Proteus are free and open-source processes its pleasing to see standards based on so much flexibility and free sharing of captures integrated seamlessly into a more expansive and considered plugin. If youre already using any of these capture formats, the CODEX aspect of Genome should make it a very appealing prospect indeed, as it allows for an efficient and controllable way of integrating them into a live or recorded workflow.

As mentioned, the sounds from Genome are pretty damn good, and it seems Two Notes plans to add more free and paid gear with updates. But, right now, its still very comprehensive as a plugin really, if you were looking at something like ToneX but the price tag was putting you off, you might find Genome offers a more affordable and focused alternative. The seamless compatibility with third-party amp captures is great to see, too and there is a free trial, so, if youre curious, why not have a try yourself?

Pros:

Cons:

As mentioned, ToneX (199.99) is perhaps the most obvious competitor, and its tiered pricing might or might not work better for you than Genomes approach to expandability. Theres also Guitar Rig, Positive Grids BIAS AMP 2, and if you want a very focused set of virtual gear Neural DSPs various suites.

Read more:
Two Notes Genome review could this no-nonsense guitar plugin be all you need? - Guitar.com

Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S.

Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S. Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240522093513/en/

L to R: Jehee Suh, CEO of Inocras, Tae-You Kim, CEO of IMBdx (Photo: Business Wire)

Inocras specializes in cancer profiling using whole genome sequencing (WGS), capturing over 99% of an individual's genomic makeup. This allows for a broader analysis of mutations and complex variations, allowing for deeper insights into a patient's condition. IMBdx has developed a comprehensive portfolio of liquid biopsies for the cancer diagnosis and treatment cycle. The company was recently listed on the KOSDAQ in South Korea.

The partnership will focus on Inocras providing IMBdxs liquid biopsy-based cancer diagnostics in the U.S. market, creating alternatives for patients and their providers when genetic testing from tissue biopsy is not feasible. This joint initiative introduces a new model of patient care, leveraging advanced two technologies in genetic testing - whole genome data and liquid biopsy.

"Our collaboration with IMBdx marks a significant step forward in our mission to transform healthcare for cancer and rare disease patients," said Jehee Suh, CEO of Inocras. "We think of patients at the core and are trying to create more options for patients and providers. By combining our strengths, we're not just delivering advanced diagnostic services, we're contributing to creating a pathway to a more effective cancer care journey.

About Inocras Inc:

Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics for cancer and rare diseases. The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone. For more information about Inocras and our services, please visit Inocras.com.

About IMBdx:

IMBdx is at the forefront of liquid biopsy technology, developing advanced diagnostic tools that capture and analyze circulating biomarkers to detect and monitor diseases more effectively and non-invasively.

Sohee Cho / media@inocras.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522093513/en/

Link:
Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S. - Morningstar

The rectangular-shaped petri dish used to collect air, water, and surface samples on the International Space Station. Credit: Georgia Tech

The Genomic Enumeration of Antibiotic Resistance in Space (GEARS) project successfully completed on-orbit genomic sequencing of microbes isolated from the ISS on April 29.

Georgia Tech Ph.D. student, Jordan McKaig, demonstrates how NASA astronauts onboard the International Space Station used the MinION sequencing device to identify bacteria genomes. Credit: Georgia Tech

All experiment slides were safely returned to Earth on SpaceX-30. The slides with the microbial samples from the GEARS spaceflight experiment were retrieved from the cold stow team and successfully transferred to the Johnson Space Center (JSC) Microbiology Laboratory on May 4.

The JSC team will work to subculture and identify all microorganisms present. The isolates will also be archived. Additionally, comparison of the returned plates to the photos obtained in-flight is in work (prior to crew manipulation of the colonies). The Co-Investigator team is conducting the preliminary screening of retrieval of bacteria.

GEARS is a series of four experiments that will survey the space station for antibiotic resistant organisms. On-board sequencing of isolates aims to show how these bacteria adapt to the space environment, providing knowledge that informs measures to protect astronauts on future long-duration missions.

Image: On-orbit sequencing of microbes isolated from the ISS for the GEARS mission.

Astrobiology

Explorers Club Fellow, ex-NASA Space Station Payload manager/space biologist, Away Teams, Journalist, Lapsed climber, Synaesthete, NaVi-Jedi-Freman-Buddhist-mix, ASL, Devon Island and Everest Base Camp veteran, (he/him)

Go here to read the rest:
Genomic Enumeration of Antibiotic Resistance in Space (GEARS) Completes Mission Operations - Astrobiology - Astrobiology News

WEST PALM BEACH, Fla., May 21, 2024 (Newswire.com) - Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit (NICU) revealed substantial transmission of infection not detected by conventional infection control procedures. The findings demonstrate that even in highly resourced medical centers and in wards like the NICU with high levels of constant vigilance, WGS enables the detection of transmission not achievable with methods in current practice. The abstract reporting the results of the study will be presented for publication at the American Society for Microbiology Conference in Atlanta on June 15.

We found that WGS of S. aureus isolates obtained from surveillance swabs and clinical samples revealed a significant amount of likely transmission, which provided guidance enabling our infection control team to take a series of actions with beneficial effect, said Dr. Romney Humphries, Professor of Pathology, Microbiology and Immunology and Director of Laboratory Medicine at VUMC and senior author on the study. The findings were notable in the apparent transmission discovered when WGS was utilized, noted first author Dr. David Gaston, Assistant Professor and Medical Director of Molecular Infectious Disease Laboratory of VUMC. Moreover, we were struck by the observation that transmission was more likely to occur with MRSA versus MSSA infection, and occurred in multiple networks rather than a single outbreak.

In the study, 171 S. aureus samples from 132 distinct patients, obtained from surveillance sampling conducted in April, June and July supplemented with clinical samples, were short-read sequenced and bioinformatically analyzed for relatedness of core genomes at the SNP level by the NGD automated system1, with a strict (6 SNP) cutoff used to identify putative transmission for assessment and action by the VUMC infection prevention team. 42/132 (31.8%) of patients with S. aureus infections were found to be putatively connected by transmission, with the percentage of patients with MRSA infections connected by transmission (46.8%) over twice the frequency in patients with MSSA infection (21.2%). 13 distinct strains were involved in transmission, suggesting localized undetected causes of spread rather than a ward-level outbreak.

NGD was privileged to have the opportunity to work with the very distinguished team at VUMC to employ NGDs automated bioinformatic systems to facilitate the use of WGS to detection of transmission in a setting such as a NICU, noted Dr. Paul A. Rhodes, founder and CEO of NGD. The demonstration that comparison of WGS so readily enabled detection of transmission that was not otherwise observed even in a state-of-the-art medical setting and in a vigilantly monitored ward was striking.

This result, along with those emerging from other medical centers2, of the use of WGS to detect rather than simply verify transmission may signal a sea-change in best practice, noted Tom Talbot, Professor of Medicine and Medical Director of Infection Prevention at VUMC. With a sufficiently low cost for sequencing and bioinformatic analysis, use of WGS to detect transmission, at least in those wards where patients are at the greatest risk, may become a more routine infection prevention practice.

1Brown et al 2019, J Clinical Microbiology 2Sundermann et al 2022, Antibiotic Stewardship and Healthcare Epidemiology

About Next Gen Diagnostics NGD offers integrated high-volume turn-key sequencing and bioinformatic services to enable detection of transmission in hospitals, and is working with leading collaborators in the U.S., Europe and Israel to be among the first to bring WGS-based regulated diagnostics to patient care. NGD is based in the U.S., with subsidiaries in Cambridge, UK and in Israel.

Source: Next Gen Diagnostics

See original here:
Next Gen Diagnostics and Vanderbilt Report the Use of Whole Genome Sequencing to Detect Transmission of Infection ... - Newswire

NEW YORK, May 22, 2024 /PRNewswire/ -- The globalgenome editing marketsize is estimated to grow by USD 7.23 billionfrom 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost15.88% during the forecast period.

For more insights on the forecast market size and historic data (2018 - 2022)-Request asample report!

Genome Editing Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 - 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 15.88%

Market growth 2024-2028

USD 7.23 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

14.56

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Canada, UK, Germany, and China

Key companies profiled

AstraZeneca PLC, Caribou Biosciences Inc., Cellectis SA, Cibus, Danaher Corp., Editas Medicine Inc., Egenesis, GenScript Biotech Corp., Horizon Discovery Ltd., Intellia Therapeutics Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs Inc., OriGene Technologies Inc., PerkinElmer Inc, Precision BioSciences Inc., Sangamo Therapeutics Inc., Takara Bio Inc., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

Advancements in genome editing technologies like CRISPR-Cas9 and base editing offer precise modifications to DNA, expanding research and therapy applications. High-throughput screening methods accelerate discovery of gene functions and drug targets.

Automation streamlines workflows, reducing errors and increasing efficiency in large-scale experiments. Bioinformatics tools optimize editing protocols and assess outcomes, enhancing reliability and safety. These advancements drive growth in the global genome editing market.

MarketChallenges

Research report provides comprehensive data on impact of trend, driver and challenges-Request asample report!

Segment Overview

1.1Pharmaceutical and biotechnology companies-During the forecast period, the pharmaceutical and biotechnology companies segment is expected to experience significant market share growth. Genome exploration enables researchers to study gene function and disease mechanisms, aiding drug discovery and personalized medicine. By inducing genetic mutations in target genes, scientists gain insights into disease biology and drug responses.

The segment, valued at USD 1.86 billion in 2018, benefits from genome-edited models for preclinical drug screening and personalized therapy development, improving treatment outcomes. CRISPR/Cas9 technology drives genetic engineering advancements, offering versatile applications in therapy development and research. Pharmaceutical and biotech firms increasingly adopt gene editing tools for drug discovery and viral vector production, fueling market expansion.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

Research Analysis

The genome editing market encompasses the development and application of advanced tools and technologies for modifying single genes within an organism's genome. These innovations hold significant promise in addressing various genetic abnormalities, including sickle cell disease, Parkinson's disease, hearing loss, and others. Gene-editing technologies, such as CRISPR-Cas9, SMR, Pro-code, and others, are revolutionizing molecular biology by enabling precise alterations to DNA strands.

Clinical trials are underway for numerous conditions, including AIDS, cancer, cystic fibrosis (CF), hemophilia, sickle cell disease, multiple myeloma, and breast cancer. Gene therapy and gene editing are expected to bring transformative treatments for tumors and other diseases. Key applications include agriculture, particularly in white button mushrooms, and industrial biotechnology.

Market Research Overview

The Genome Editing Market refers to the industry focused on developing and implementing technologies that enable the precise modification of an organism's DNA. This innovative field combines the use of tools like CRISPR-Cas9, zinc finger nucleases, and TALENs to target specific genes and make desired changes. Genome editing holds significant potential in various sectors, including agriculture, medicine, and research.

Its applications range from creating disease-resistant crops to treating genetic disorders and enhancing protein production. The technology's versatility and potential to revolutionize numerous industries continue to drive its growth and global interest.

Table of Contents:

1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation

7Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email:[emailprotected] Website:www.technavio.com/

SOURCE Technavio

Read more:
Genome Editing Market size is set to grow by USD 7.23 billion from 2024-2028, Rapid technological advancements in ... - PR Newswire